Ranbaxy Lab Peer Comparison

NSE: RANBAXY | BSE: 500359

₹859.80

₹45.80 (5.63%)

As on 01-Apr-2015IST

Market cap

₹36,603 Cr

Revenue (TTM)

₹5,759 Cr

P/E Ratio

P/B Ratio

Div. Yield

0 %

Edit

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	36,603	32,758	32,619	32,170	28,669
Revenue (₹ Cr)	5,759	9,779	3,751	1,593	2,100
Net Profit (₹ Cr)	-135.76	-270.51	405.00	438.64	324.79
Net Margin (%)	-2.08	-2.71	10.48	27.16	15.36
RoE (%)	-10.47	-2.55	7.91	25.02	24.02
Price to Earnings	--	--	79.56	73.25	88.26
Price-To-Book	13.98	4.02	6.32	17.32	20.24

Income Statement (₹ Cr)

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Operating Revenue	12,459.73	--	4,350.50	33.90	34.80
Total Income	12,750.46	--	4,375.84	34.61	34.80
Total Expenditure	10,654.56	--	2,996.79	30.42	25.65
EBITDA	1,805.16	--	1,353.71	3.48	9.15
Depreciation	320.25	--	115.07	1.05	2.71
EBIT	1,484.92	--	1,238.64	2.42	6.44
Interest	303.60	--	269.02	1.10	2.51
Other Income	290.74	--	25.34	0.71	0.42
Exceptional Items	-227.16	--	-473.77	--	--
Profit before Tax	1,244.89	--	521.19	2.03	3.93
Provision for Tax	293.90	--	221.74	0.68	1.40
Profit after Tax	950.99	--	299.45	1.35	2.52

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	4,084.33	--	1,471.02	6.11	37.49
Minority Interest	88.95	--	--	--	--
Non-Current Liabilities	3,277.61	--	2,891.88	0.04	5.39
Current Liabilities	8,965.45	--	1,890.94	15.82	24.92
Total Liabilities	16,452.00	--	6,253.84	22.09	67.79

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Non-Current Assets	6,404.00	--	3,772.33	5.51	47.64
Current Assets	10,012.33	--	2,481.51	16.45	20.15
Total Assets	16,452.00	--	6,253.84	22.09	67.79
Total Debt*	4,901.30	--	3,492.50	6.41	19.14
Net Current Assets	1,046.89	--	590.57	0.63	-4.76
Contingent Liabilities	284.58	--	46.91	--	0.71

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	1,582.10	--	1,343.83	--	5.07
Cash Flow from Investing Activities	-1,820.32	--	-305.45	--	-4.60
Cash from Financing Activities	236.92	--	-826.56	--	-0.83
Net Cash Inflow / Outflow	-1.29	--	211.82	0.00	-0.36

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
ROCE (%)	18.96	--	16.20	25.61	12.09
ROE (%)	27.53	--	66.74	24.87	14.65
ROA (%)	5.93	--	4.97	6.42	4.06
EBIT Margin (%)	16.82	--	31.70	12.34	26.29
Net Margin (%)	7.46	--	6.84	3.90	7.25
Cash Profit Margin (%)	10.18	--	9.52	6.56	15.04

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	20.63	--	15.97	21.86	65.29
EBIT Growth (%)	19.87	--	29.05	27.63	42.04
Net Profit Growth (%)	132.98	--	212.90	7.55	6.25
EPS Growth (%)	131.75	--	278.36	7.55	6.25
Book Value Growth (%)	42.35	--	253.45	28.51	15.81

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Price / Earnings	23.04	--	17.64	0.00	0.00
Price / Book Value	5.24	--	9.37	0.00	0.00
Dividend Yield (%)	0.00	--	0.00	--	--
EV/EBITDA	10.29	--	7.33	1.71	4.36
Market Cap (₹ Cr)	21,262.00	--	6,555.46	0.00	0.00

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debt to Equity	1.21	--	2.39	1.05	0.51
Short term debt to equity ratio	0.70	--	0.18	0.88	0.21
Current Ratio	1.12	--	1.31	1.04	0.81
Quick Ratio	0.81	--	0.84	0.66	0.77
Interest Coverage	5.10	--	2.94	2.86	2.57

	Ranbaxy Lab	Piramal Pharma	Wockhardt	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	16.35	--	17.44	24.27	42.51
Asset Turnover	0.78	--	0.72	1.74	0.56
Receivable days	73.69	--	57.17	81.45	120.33
Inventory Days	78.07	--	67.16	45.36	9.04
Payable days	66.78	--	116.25	134.63	535.25
Cash Conversion Cycle	84.98	--	8.07	-7.82	-393.94

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.